Tirzepatide denied for failing step therapy by Cigna?

Cigna's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Requires Step Therapy for Tirzepatide — and Why You Can Appeal

Step-therapy (also called "fail-first") denials from Cigna for tirzepatide mean the plan requires you to try and fail one or more alternative medications before it will authorize tirzepatide. These policies are common for newer branded medications but are not absolute — federal and state law, plus your clinical history, may override them.

## Why This Denial Is Appealable

Step-therapy requirements can be overridden when: (a) you have already tried and failed or had a contraindication to the required prior medications, (b) the step-therapy requirement conflicts with applicable clinical guidelines from recognized organizations such as the ADA or Obesity Medicine Association, or (c) requiring the prior steps would cause clinically significant delay or harm. Many states have enacted step-therapy exception laws that impose strict timelines on insurers to respond to exception requests.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 (employer plan) or your state's insurance code. The denial letter must state your deadline — typically 180 days.
• External review: Under ACA §2719, if the internal appeal is denied, you may escalate to an independent external review organization. The external-review window is generally within approximately four months of the final internal denial. External-review decisions are binding.
• Expedited review: Available when standard timelines would seriously jeopardize your health; typically decided within 72 hours.

## Concrete Appeal Steps

1. Pull the denial letter and identify every drug Cigna requires you to try first. 2. With your prescriber, audit your medication history against that list — document each prior agent tried, dates, doses used, and why it failed or was not tolerable. 3. If you have not tried a required prior drug, ask your prescriber to document any clinical reason it is inappropriate for you (allergy, interaction concern, contraindication per label) — do not assert the clinical fact yourself; let the licensed prescriber do so. 4. Request Cigna's step-therapy exception form if one exists, and submit it alongside your internal appeal. 5. If denied, file for external review.

## Documentation to Gather

• Medication history: Pharmacy records and chart notes listing every prior anti-obesity or diabetes medication, dates of use, and documented response or adverse effect.
• Prescriber letter: Clinical rationale for why tirzepatide is appropriate now and why step-therapy alternatives are inadequate or contraindicated for this patient.
• Diagnosis and severity documentation: Chart notes establishing diagnosis and clinical status, supporting why delay causes harm.
• Applicable guideline reference: Your prescriber should cite the relevant guideline organization (e.g., ADA Standards of Care, relevant obesity-medicine society guidance) to establish that tirzepatide is a recognized standard-of-care option.

## Criteria-Mapping Structure

List each step-therapy requirement from Cigna's policy verbatim. For each, provide the chart-based response: either the documented failure of that prior agent, or the prescriber's documented clinical reason it is contraindicated. Attach pharmacy records and chart notes as exhibits. A clear one-to-one mapping reduces reviewer discretion and strengthens your appeal.